21.02.2022 • News

Catalent Expands China Clinical Capabilities

US CDMO Catalent plans to expand its facility in Shanghai, China, doubling capacity for the temperature-controlled storage and distribution of clinical supplies and adding secondary packaging capabilities. The expansion is expected to be completed by the middle of this year.

“We have seen great demand for clinical supply services in China. This expansion will increase both capacity and capabilities at the Shanghai facility, and makes provision for the growing trend in clinical trials of advanced therapeutics requiring specialized storage and handling capabilities, including deep-frozen for emerging biotech companies,” said Roel de Nobel, vice president and general manager, APAC, clinical supply services.

The facility in the Waigaoqiao Free Trade Zone is one of two clinical supply sites that Catalent operates in Shanghai – the other, which opened in April 2019, is located in Tangzhen. Together, said Catalent, they provide sponsors with optimized supply solutions for studies performed both in China and Asia-Pacific, as well as worldwide.

Author: Elaine Burridge, Freelance Journalist

(c) Denys Nevozhai
(c) Denys Nevozhai

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

most read